Impact of Treatment with Anti-CD20 Monoclonal Antibody on the Production of Neutralizing Antibody Against Anti-SARS-CoV-2 Vaccination in Mature B-Cell Neoplasms.
Akio OnishiYayoi Matsumura-KimotoShinsuke MizutaniTaku TsukamotoTakahiro FujinoAkihiro MiyashitaDaichi NishiyamaKazuho ShimuraHiroto KanekoEri KawataRyoichi TakahashiTsutomu KobayashiHitoji UchiyamaNobuhiko UoshimaYoko NukuiYuji ShimuraTohru InabaJunya KurodaPublished in: Infection and drug resistance (2023)
The use of anti-CD20 MoAb within 12 months before vaccination is a critical risk for poor Ab response against anti-SARS-CoV-2 vaccination in patients with BCL.